Compare LMB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMB | COLL |
|---|---|---|
| Founded | 1901 | 2002 |
| Country | United States | United States |
| Employees | 1400 | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2014 | 2015 |
| Metric | LMB | COLL |
|---|---|---|
| Price | $80.69 | $32.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $116.67 | $51.17 |
| AVG Volume (30 Days) | 181.9K | ★ 547.7K |
| Earning Date | 03-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.68 | N/A |
| EPS | ★ 3.23 | 1.73 |
| Revenue | $646,804,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $15.96 | $5.93 |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $24.90 | ★ $19.32 |
| Revenue Growth | ★ 24.68 | 23.62 |
| 52 Week Low | $63.02 | $23.23 |
| 52 Week High | $154.04 | $50.79 |
| Indicator | LMB | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 24.32 |
| Support Level | $77.96 | $31.01 |
| Resistance Level | $85.30 | $32.92 |
| Average True Range (ATR) | 4.28 | 1.30 |
| MACD | 0.37 | -0.04 |
| Stochastic Oscillator | 65.93 | 1.07 |
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.